Key result
GSK2795039 attenuates TNF-α-induced cardiomyocyte necroptosis and apoptosis by suppressing Nox2 and ROS.
Why the study?
TNF-α induces ROS and necroptosis in cardiomyocytes, contributing to heart failure, and it was unknown whether the novel NADPH oxidase 2 inhibitor GSK2795039 prevents TNF-α-induced cardiomyocyte necroptosis and through what underlying mechanisms.
Does the Nox2 inhibitor GSK2795039 prevent TNF-α-induced RIP1-RIP3-MLKL-mediated necroptosis and apoptosis in cultured H9C2 cardiomyocytes?
Does the Nox2 inhibitor GSK2795039 prevent TNF-α-induced RIP1-RIP3-MLKL-mediated necroptosis and apoptosis in cultured H9C2 cardiomyocytes?
This preclinical study demonstrates for the first time that the specific Nox2 inhibitor GSK2795039 prevents TNF-α-induced cardiomyocyte necroptosis and apoptosis in vitro by inhibiting NADPH oxidase-derived ROS and the RIP1-RIP3-MLKL pathway, supporting further evaluation in animal models of heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Nox2 inhibition in TNF-α-driven cardiomyocyte death; requires in vivo validation before any clinical consideration.
Inflammatory cytokines and oxidative stress contribute to heart failure. Tumor necrosis factor-α (TNF-α), a major inflammatory cytokine, induces reactive oxygen species (ROS) and necroptosis in cardiomyocytes. GSK2795039 is a novel NADPH oxidase 2 inhibitor. However, it is unknown whether GSK2795039 prevents TNF-α-induced cardiomyocyte necroptosis and the underlying mechanisms. In the present study, we tested the hypothesis that GSK2795039 prevents TNF-α-induced necroptosis in cardiomyocytes through inhibition of NADPH oxidase-mediated RIP1-RIP3-MLKL pathway. The H9C2 cardiomyocytes were divided into the following groups: control, necrostatin-1, TNF-α, and TNF-α plus necrostatin-1; control, GSK2795039, TNF-α, and TNF-α plus GSK2795039. ROS were assessed by dihydroethidium staining. Necroptotic and apoptotic proteins were measured by Western blot. The RIP1 inhibitor necrostatin-1 attenuated apoptosis, necrosis, phosphorylated RIP3 (p-RIP3) and p-MLKL protein and intracellular ROS in TNF-α-treated H9C2 cardiomyocytes. GSK2795039 inhibited TNF-α-induced Nox2 expression, intracellular ROS and cell death. GSK2795039 prevented the increases in phosphorylated RIP1 (p-RIP1), p-RIP3 and p-MLKL proteins, reflective of their respective kinase activities, markers of necroptosis, in TNF-α-treated H9C2 cardiomyocytes. GSK2795039 prevented the decrease in anti-apoptotic Bcl-2 protein and the increases in pro-apoptotic Bax protein, phosphorylated JNK protein and cleaved caspase 3 protein, indicative of caspase activity, a marker of apoptosis, in TNF-α-treated H9C2 cardiomyocytes. The results indicate that GSK2795039 prevented TNF-α-induced RIP1-RIP3-MLKL-mediated necroptosis in H9C2 cardiomyocytes through inhibition of NADPH oxidase-derived ROS. These findings advocate for further animal testing of the specific Nox2 inhibitor GSK2795039 in myocardial infarction and heart failure, which are characterized by elevated levels of inflammatory cytokines such as TNF-α and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied TNF-α-induced cardiomyocyte necroptosis and apoptosis (in vitro model of heart failure). GSK2795039 vs. TNF-α alone (50 ng/ml) and untreated DMEM control was evaluated on RIP1-RIP3-MLKL-mediated necroptosis (p-RIP1, p-RIP3, p-MLKL expression and necrotic cell death) and intracellular ROS production (p=<0.05). GSK2795039 (25 μM) inhibited TNF-α-induced Nox2 expression, intracellular ROS, and RIP1-RIP3-MLKL-mediated necroptosis and apoptosis in H9C2 cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: